This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schneider, B. P. Articles by Carey, L. A. Search for Related Content PubMed Articles by Schneider, B. P. Articles by Carey, L. A. Related Collections Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers Clinical Research: Imaging, Diagnosis, and Prognosis

Triple-Negative Breast Cancer: Risk Factors to Potential Targets

Authors' Affiliations: ¹ Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana; ² The Dana-Farber Cancer Institute, Boston, Massachusetts; ³ Program in Cancer Genetics, McGill University, Montreal, Canada; and ⁴ University of North Carolina, Chapel Hill, North Carolina

Requests for reprints: Bryan P. Schneider, Indiana Cancer Pavilion, Room 473, 535 Barnhill Drive, Indianapolis, IN 46202. Phone: 317-274-6473; Fax: 317-274-3646; E-mail: bpschnei{at}iupui.edu.

Abstract

Triple-negative breast cancer has recently been recognized as an important subgroup of breast cancer with a distinct outcome and therapeutic approach when compared with other subgroups of breast cancer. Triple-negative breast cancer comprises primarily, but not exclusively, a molecularly distinct subtype of breast cancer, the basal-like subtype. We do not yet have an assay to identify basal-like breast cancer in clinical samples, so triple-negative breast cancer has become a commonly used proxy for this subtype. The molecular biology and pathophysiology of triple-negative breast cancer are not completely understood, but understanding is improving rapidly with the advent of sophisticated molecular biology platforms. Moreover, the established risk factors of breast cancer as a whole may not apply to this unique subgroup of patients. Finally, because triple-negative breast cancer is defined by the absence of a target, there are currently limitations to using a tailored therapeutic approach, leaving conventional cytotoxic therapies as the mainstay. Active preclinical and clinical research programs focus on defining the clinical behavior, delineating the risk factors, and more completely understanding the molecular biology of triple-negative breast cancer to improve prevention, optimize conventional agents, and unveil novel therapeutic targets. This CCR focus article will review the current state of the art on triple-negative breast cancer.

This article has been cited by other articles:

				B. C. Pestalozzi Brain metastases and subtypes of breast cancer Ann. Onc., May 1, 2009; 20(5): 803 - 805. [Full Text] [PDF]

				T. Heikkinen, H. Karkkainen, K. Aaltonen, R. L. Milne, P. Heikkila, K. Aittomaki, C. Blomqvist, and H. Nevanlinna The Breast Cancer Susceptibility Mutation PALB2 1592delT Is Associated with an Aggressive Tumor Phenotype Clin. Cancer Res., May 1, 2009; 15(9): 3214 - 3222. [Abstract] [Full Text] [PDF]

				O. I. Olopade, T. A. Grushko, R. Nanda, and D. Huo Advances in Breast Cancer: Pathways to Personalized Medicine Clin. Cancer Res., December 15, 2008; 14(24): 7988 - 7999. [Abstract] [Full Text] [PDF]

				S.-H. Tan, S.-C. Lee, B.-C. Goh, and J. Wong Pharmacogenetics in Breast Cancer Therapy Clin. Cancer Res., December 15, 2008; 14(24): 8027 - 8041. [Abstract] [Full Text] [PDF]